Keyphrases
Cancer Patients
100%
Cancer Treatment
9%
Chemotherapy
18%
Clinical Trials
9%
Comparisons with a Control
9%
Confidence Interval
63%
Epidermal Growth Factor Receptor
9%
Erlotinib
100%
Fixed Effects Model
9%
In Cancer
100%
Meta-analysis
100%
Prospective Randomized Trial
9%
Random Effects
9%
Randomized Controlled Clinical Trial
27%
Rash
27%
Relative Risk
27%
Risk Ratio
9%
Skin Rash
100%
Solid Tumors
9%
Starting Dose
9%
Systematic Meta-analysis
9%
Treatment Trials
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
18%
Clinical Trial
9%
Controlled Clinical Trial
27%
Epidermal Growth Factor Receptor
9%
Erlotinib
100%
Malignant Neoplasm
100%
Rash
100%
Side Effect
9%
Skin Toxicity
18%
Solid Malignant Neoplasm
9%